Pulmatrix Inc (PULM)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.52+14.29%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · PULM
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -44.3% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 5.3% |
Growth built into the price is above our model estimate.
The price assumes 49.5 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers · Company calendar date is not available
PULM — private placement
Dated 2026-04-21
Other Events On April 16, 2026, the Company closed its previously announced private placement of its Series B Preferred Stock, par value $0.0001 per share (the “ Private Placement ”). The Private Placement was exempt from the registration requirements of the Securities Act pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D of the Securities Act and in reliance on similar exemptions…
Why it matters: Cash and cash equivalents fell to $2.2 million by June 30. Management said funds covered operations through the expected merger close, not beyond it.
Worry ifA filing shows cash and cash equivalents below $2.2 million, with no merger close or new funding disclosed.
Less concerning ifThe merger closes or new funding is disclosed before cash falls below $2.2 million.
Why it matters: Lower costs have helped conserve cash, but the company remains loss-making. Higher costs could shorten the time available to close the merger or fund other work.
Worry ifA later quarter reports general and administrative costs over $1.0 million. Cash is below $2.2 million.
Less concerning ifGeneral and administrative costs stay at or below $1.0 million and cash stays at or above $2.2 million.
Why it matters: Pulmatrix targeted a Q3 2026 close, but the latest update was in August. A closing or a clear delay would change the company’s next step.
Watch forA company filing confirms the Eos merger closed. It also lists the combined company’s next steps.
Also watch forA filing reports that the merger ended, or gives a new close date after Q3 2026.
Why it matters: Cipla has approval to start Phase 3 and said it planned to begin in 2026. Trial start would advance an asset that may bring Pulmatrix royalties.
Supportive ifCipla or Pulmatrix reports that the PUR1900 Phase 3 trial has begun in India during 2026.
Worry ifNo trial start is reported by year-end 2026, or Cipla reports a delay or cancellation.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$260 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $591 loss on $10,000 · 5.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,567 loss on $10,000 · 75.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.